secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATAI Life Sciences N.V. (—)
CIK:        0001840904
Form:       8-K
Filed at:   2024-05-23T23:59:59+00:00
Accession:  0001140361-24-027226
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

atai Life Sciences appoints two new independent directors; Camm departs board
-----------------------------------------------------------------------------

- Scott Braunstein, M.D. and Laurent Fischer, M.D. appointed as independent supervisory directors, subject to Dutch registration.
- Jason Camm stepped down after four years; resignation not due to any disagreement with the company.
- New directors bring pharma executive experience as atai advances to later-stage clinical trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840904/000114036124027226/0001140361-24-027226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840904/000114036124027226/ef20029704_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-027226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer